Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study

Philip J. Mease, Dafna D. Gladman, Atul Deodhar, Dennis G. McGonagle, Peter Nash, Wolf Henning Boehncke, Alice Gottlieb, Xie L. Xu, Stephen Xu, Elizabeth C. Hsia, Chetan S. Karyekar, Philip S. Helliwell

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Fingerprint

Dive into the research topics of 'Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study'. Together they form a unique fingerprint.

Medicine & Life Sciences